Home » Abbott Targets Amneal in Latest Fight Over Generic Niaspan
Abbott Targets Amneal in Latest Fight Over Generic Niaspan
Abbott Laboratories’ AbbVie hit Amneal Pharmaceuticals with a patent suit in Delaware Federal Court, arguing that Amneal has infringed a patent covering its cholesterol medication, Niaspan.
Law360
Law360
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May